Arkstone Files Patents Focused on Helping Physicians Prescribe Responsibly

Arkstone Medical Solutions, the leading provider of infectious disease laboratory result interpretations, today announced that it has filed Provisional U.S. Patent Applications covering technologies that aid physicians in making educated and informed decisions for patient care. These systems are already in use on the renowned Arkstone Report, which analyzes molecular diagnostic lab results and guides physicians with pinpoint interpretations and recommendations.The OneChoice™ decision engine combines artificial intelligence and machine learning with decades of deep infectious disease human expertise to guide physicians to a singular treatment regimen based on organisms detected in molecular diagnostic tests. When treating infectious disease and choosing a course of antibiotics, a physician must balance a number of factors. They must determine which organisms are pathogenic and which need to be treated as well as whether resistance genes were detected or the patient has allergies that would limit antibiotic choices. Often physicians prescribe a number of different antibiotics instead of a singular treatment regimen. OneChoice™ weighs dozens of variables and determines the most appropriate antibiotic regimen given the factors present. These factors include the source of infection, organisms and resistance genes detected, patient allergies, age and sex, and then recommends the most optimal course of treatment with the lowest risk to the patient."Arkstone is committed to reducing the global spread of antimicrobial-resistant bacteria and the misuse of antibiotics through continued education, advanced technology, and guidance to the medical community. By guiding physicians to "one choice" we are ensuring that fewer antibiotics are prescribed, and those that are a most effective," said Dr. Ari Frenkel, Chief Science Officer and co-founder of Arkstone, "In many instances, such as cases of viral infections that are self-limiting, OneChoice™ will recommend that no antibiotics be administered at all."

This patent further complements the HIPAA-compliant, proprietary products that Arkstone offers laboratories, skilled nursing facilities, and hospitals nationwide. "OneChoice™ works in conjunction with the ArkScore™ system, another of our patent-pending technologies, which allows physicians to easily see the severity of resistance genes or compare the risk factors of different antibiotics," added Dave Gross, Chief Technology Officer and co-founder of Arkstone. The ABX ArkScore provides important information to prescribers about antibiotics. Higher scores indicate safety, effectiveness, and less risk associated with the use of the antibiotic. The AMR ArkScore measures levels of antimicrobial resistance expressed in detected organisms. Lower scores indicate increased levels of resistance, limiting the antibiotic options available, and increased risk to the patient.